X

Drug Profile

Anti-CD64-anti-CD30 bispecific monoclonal antibody - Medarex

Alternative Names: H22xKi-4

Latest Information Update: 03 May 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medarex
Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
Mechanism of Action CD30 antigen inhibitors; IgG receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hodgkin's disease
New Molecular Entity Yes

Highest Development Phases

Discontinued Hodgkin's disease

Most Recent Events

03 May 2007 Discontinued - Phase-I for Hodgkin's disease in USA (unspecified route)
03 Apr 2003 Phase-I clinical trials in Hodgkin's disease in USA (unspecified route)
03 Apr 2003 A study has been added to the adverse events, pharmacokinetics, pharmacodynamic and Cancer therapeutic trials sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com